NASDAQ:ONTX - Onconova Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.50
  • Forecasted Upside: 50.00 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.00
▼ -0.23 (-4.40%)

This chart shows the closing price for ONTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Onconova Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONTX

Analyst Price Target is $7.50
▲ +50.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Onconova Therapeutics in the last 3 months. The average price target is $7.50, with a high forecast of $11.00 and a low forecast of $4.00. The average price target represents a 50.00% upside from the last price of $5.00.

This chart shows the closing price for ONTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Onconova Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/29/2021Noble FinancialReiterated RatingBuy$11.00Low
5/18/2021GuggenheimInitiated CoverageBuy$4.00High
12/22/2020Noble FinancialUpgradeMarket Perform ➝ OutperformLow
11/13/2020Maxim GroupReiterated RatingHoldMedium
8/25/2020Noble FinancialDowngradeOutperform ➝ Market PerformLow
8/24/2020LaidlawDowngradeBuy ➝ HoldHigh
8/24/2020Maxim GroupDowngradeBuy ➝ HoldHigh
8/24/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
8/13/2020Noble FinancialReiterated RatingBuy$19.50High
8/3/2020Noble FinancialReiterated RatingBuyLow
7/27/2020HC WainwrightReiterated RatingBuy$30.00Medium
6/23/2020Maxim GroupInitiated CoverageBuy$18.75Medium
6/15/2020Noble FinancialReiterated RatingBuy$19.50Medium
5/15/2020Maxim GroupUpgradeHold ➝ Buy$18.75High
3/25/2020HC WainwrightReiterated RatingBuyHigh
12/27/2019Noble FinancialReiterated RatingBuy$19.50High
11/26/2019Maxim GroupDowngradeBuy ➝ HoldHigh
10/29/2019Noble FinancialReiterated RatingBuy$180.00High
9/9/2019Maxim GroupSet Price TargetBuy$120.00Low
8/12/2019Maxim GroupSet Price TargetBuy$120.00Medium
7/25/2019Noble FinancialInitiated CoverageOutperform$180.00High
5/14/2019HC WainwrightSet Price TargetBuy$375.00Medium
5/14/2019Maxim GroupReiterated RatingBuy$240.00High
3/26/2019HC WainwrightSet Price TargetBuy$375.00High
3/25/2019Maxim GroupReiterated RatingBuy$240.00Low
2/8/2019HC WainwrightReiterated RatingBuy$375.00Low
12/3/2018HC WainwrightSet Price TargetBuy$375.00High
12/3/2018Maxim GroupSet Price TargetBuy$240.00High
11/14/2018HC WainwrightSet Price TargetBuy$375.00High
11/13/2018Maxim GroupSet Price TargetBuy$240.00High
10/11/2018Maxim GroupLower Price TargetBuy$675.00 ➝ $240.00Medium
9/27/2018HC WainwrightReiterated RatingBuy$375.00Medium
8/14/2018HC WainwrightSet Price TargetBuy$675.00High
8/14/2018Maxim GroupReiterated RatingBuy$675.00High
5/15/2018HC WainwrightSet Price TargetBuy$675.00High
5/2/2018Maxim GroupUpgradeHold ➝ BuyMedium
3/26/2018HC WainwrightSet Price TargetBuy$1,800.00Low
3/26/2018Maxim GroupReiterated RatingHoldLow
3/9/2018HC WainwrightReiterated RatingBuy$1,800.00Low
3/8/2018Maxim GroupReiterated RatingHoldLow
3/2/2018Maxim GroupReiterated RatingHoldMedium
3/1/2018HC WainwrightReiterated RatingBuy ➝ Buy$1,350.00 ➝ $1,687.50Low
1/18/2018HC WainwrightReiterated RatingBuy$1,350.00High
1/17/2018Maxim GroupDowngradeBuy ➝ HoldHigh
1/4/2018HC WainwrightSet Price TargetBuy$1,350.00High
12/19/2017HC WainwrightSet Price TargetBuy$1,350.00High
12/12/2017HC WainwrightSet Price TargetBuy$1,350.00Medium
11/9/2017HC WainwrightReiterated RatingBuyN/A
11/9/2017Maxim GroupSet Price TargetBuy$1,350.00N/A
11/2/2017Maxim GroupReiterated RatingBuy$1,350.00N/A
10/9/2017HC WainwrightInitiated CoverageBuy ➝ Buy$1,350.00N/A
8/15/2017Maxim GroupSet Price TargetBuy$1,350.00High
7/25/2017Dawson JamesReiterated RatingBuyHigh
6/6/2017Maxim GroupSet Price TargetBuy$1,350.00Medium
5/15/2017Maxim GroupSet Price TargetBuy$1,350.00Low
4/27/2017LaidlawInitiated CoverageBuy ➝ Buy$2,250.00Low
4/4/2017Maxim GroupReiterated RatingBuy$1,350.00High
3/27/2017Maxim GroupSet Price TargetBuy$1,350.00Low
9/26/2016Maxim GroupReiterated RatingBuy$1,350.00N/A
8/19/2016Maxim GroupReiterated RatingBuy$1,350.00N/A
8/11/2016Maxim GroupSet Price TargetBuy$1,350.00N/A
(Data available from 7/28/2016 forward)
Onconova Therapeutics logo
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Read More

Today's Range

Now: $5.00
Low: $4.88
High: $5.21

50 Day Range

MA: $6.59
Low: $0.73
High: $13.88

52 Week Range

Now: $5.00
Low: $2.85
High: $28.95

Volume

267,949 shs

Average Volume

2,181,390 shs

Market Capitalization

$78.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Onconova Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Onconova Therapeutics in the last twelve months: Guggenheim, HC Wainwright, Laidlaw, Maxim Group, Noble Financial, and Zacks Investment Research.
View the latest analyst ratings for ONTX.

What is the current price target for Onconova Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Onconova Therapeutics in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 50.0%. Noble Financial has the highest price target set, predicting ONTX will reach $11.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $4.00 for Onconova Therapeutics in the next year.
View the latest price targets for ONTX.

What is the current consensus analyst rating for Onconova Therapeutics?

Onconova Therapeutics currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ONTX, but not buy more shares or sell existing shares.
View the latest ratings for ONTX.

What other companies compete with Onconova Therapeutics?

How do I contact Onconova Therapeutics' investor relations team?

Onconova Therapeutics' physical mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company's listed phone number is 267-759-3680 and its investor relations email address is [email protected] The official website for Onconova Therapeutics is www.onconova.com.